Research Article| Volume 26, ISSUE 2, P286-294, February 2017

Download started.


Metabolic Syndrome and the Risk of Ischemic Stroke


      Metabolic syndrome (MetS) is recently proposed as a predictor for the occurrence of vascular defects causing ischemic stroke. However, details on the association of MetS with stroke are scare in our region. The present study aimed to assess the predictive value of MetS and its components for stoke among the Iranian population.


      A longitudinal population-based study was conducted on adults aged 35 years or older who were living in 3 districts in central part of Iran and followed for 10 years. Stroke was diagnosed using World Health Organization guidelines, and MetS was defined according to the Adult Treatment Panel-III definition.


      Among the 5398 subjects, 2021 suffered from MetS with an incidence of 37.4%. The incidence rates of stroke in those with and without MetS were 2.6% and 1.1%, respectively, with a higher significance in the former group (P = .026). Compared to the controls, participants with stroke exhibited a higher prevalence of some components of MetS including hyperglycemia and hypertension. On Cox proportional hazard analysis, the hazard ratio for a long-term risk of ischemic stroke was 1.37 overall (95% confidence interval: 1.15-1.63, P < .001) in subjects with MetS. Considering different components of MetS, hyperglycemia (hazard ratio = 1.83, P = .011) and hypertension (1.74, P = .019) could effectively predict occurrence of long-term ischemic stroke.


      MetS and its main components can be potent predictors for long-term ischemic stroke. Thus, the focus should be on identification and appropriate control of MetS components to prevent stroke occurrence.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Stroke and Cerebrovascular Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Air E.L.
        • Kissela B.M.
        Diabetes, the metabolic syndrome, and ischemic stroke: epidemiology and possible mechanisms.
        Diabetes Care. 2007; 30: 3131-3140
        • Tran J.
        • Mirzaei M.
        • Anderson L.
        • et al.
        The epidemiology of stroke in the Middle East and North Africa.
        J Neurol Sci. 2010; 295: 38-40
        • Oveisgharan S.
        • Sarrafzadegan N.
        • Shirani S.
        • et al.
        Stroke in Isfahan, Iran: hospital admission and 28-day case fatality rate.
        Cerebrovasc Dis. 2007; 24: 495-499
        • Sacco R.L.
        Risk factors and outcomes for ischemic stroke.
        Neurology. 1995; 45 (Review): S10-S14
        • Lai S.M.
        • Alter M.
        • Friday G.
        • et al.
        A multifactorial analysis of risk factors for recurrence of ischemic stroke.
        Stroke. 1994; 25: 958-962
        • Xu G.
        • Liu X.
        • Wu W.
        • et al.
        Recurrence after ischemic stroke in Chinese patients: impact of uncontrolled modifiable risk factors.
        Cerebrovasc Dis. 2007; 23 (Epub 2006 Nov 15): 117-120
        • Boysen G.
        • Brander T.
        • Christensen H.
        • et al.
        Homocysteine and risk of recurrent stroke.
        Stroke. 2003; 34 (Epub 2003 Apr 17): 1258-1261
        • Takano K.
        • Yamaguchi T.
        • Uchida K.
        Markers of a hypercoagulable state following acute ischemic stroke.
        Stroke. 1992; 23: 194-198
        • Liou C.W.
        • Tan T.Y.
        • Lin T.K.
        • et al.
        Metabolic syndrome and three of its components as risk factors for recurrent ischemic stroke presenting as large-vessel infarction.
        Eur J Neurol. 2008; 15: 802-809
        • Ford E.S.
        • Giles W.H.
        • Dietz W.H.
        Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.
        JAMA. 2002; 287: 356-359
        • Sattar N.
        • Gaw A.
        • Scherbakova O.
        • et al.
        Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study.
        Circulation. 2003; 108: 414-419
        • Gharipour M.
        • Kelishadi R.
        • Khosravi A.
        • et al.
        The impact of a community trial on the pharmacological treatment in the individuals with the metabolic syndrome: findings from the Isfahan Healthy Heart Program, 2001-2007.
        Arch Med Sci. 2012; 8: 1009-1017
        • Sarrafzadegan N.
        • Gharipour M.
        • Sadeghi M.
        • et al.
        Metabolic syndrome in Iranian elderly.
        ARYA Atheroscler. 2012; 7: 157-161
        • Sarrafzadegan N.
        • Talaei M.
        • Sadeghi M.
        • et al.
        The Isfahan cohort study: rationale, methods and main findings.
        J Hum Hypertens. 2011; 25: 545-553
        • Gharipour M.
        • Kelishadi R.
        • Toghianifar N.
        • et al.
        Socioeconomic disparities and smoking habits in metabolic syndrome: evidence from Isfahan healthy heart program.
        Iran Red Crescent Med J. 2011; 13: 537-543
        • Callahan A.
        • Amarenco P.
        • Goldstein L.B.
        • et al.
        Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
        Arch Neurol. 2011; 68: 1245-1251
        • Ovbiagele B.
        • Saver J.L.
        • Lynn M.J.
        • et al.
        Impact of metabolic syndrome on prognosis of symptomatic intracranial atherostenosis.
        Neurology. 2006; 66: 1344-1349
        • Chen H.J.
        • Bai C.H.
        • Yeh W.T.
        • et al.
        Influence of metabolic syndrome and general obesity on the risk of ischemic stroke.
        Stroke. 2006; 37: 1060-1064
        • Bruno G.
        • Merletti F.
        • Biggeri A.
        • et al.
        Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study.
        Diabetes Care. 2004; 27: 2689-2694
        • Sarraf-Zadegan N.
        • Sadri G.
        • Malek Afzali H.
        • et al.
        Isfahan healthy heart programme: a comprehensive integrated community-based programme for cardiovascular disease prevention and control. Design, methods and initial experience.
        Acta Cardiol. 2003; 58: 309-320
        • Aho K.
        • Harmsen P.
        • Hatano S.
        • et al.
        Cerebrovascular disease in the community: results of a WHO collaborative study.
        Bull World Health Organ. 1980; 58: 113-130
        • Sarrafzadegan N.
        • Kelishadi R.
        • Esmaillzadeh A.
        • et al.
        Do lifestyle interventions work in developing countries? Findings from the Isfahan healthy heart program in the Islamic Republic of Iran.
        Bull World Health Organ. 2009; 87: 39-50
        • Tikk K.
        • Sookthai D.
        • Monni S.
        • et al.
        Primary preventive potential for stroke by avoidance of major lifestyle risk factors: the European Prospective Investigation into Cancer and Nutrition-Heidelberg cohort.
        Stroke. 2014; 45: 2041-2046
        • McNeill A.M.
        • Rosamond W.D.
        • Girman C.J.
        • et al.
        The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study.
        Diabetes Care. 2005; 28: 385-390
        • McNeill A.M.
        • Katz R.
        • Girman C.J.
        • et al.
        Metabolic syndrome and cardiovascular disease in older people: the cardiovascular health study.
        J Am Geriatr Soc. 2006; 54: 1317-1324
        • Kurl S.
        • Laukkanen J.A.
        • Niskanen L.
        • et al.
        Metabolic syndrome and the risk of stroke in middle-aged men.
        Stroke. 2006; 37: 806-811
        • Iso H.
        • Sato S.
        • Kitamura A.
        • et al.
        Metabolic syndrome and the risk of ischemic heart disease and stroke among Japanese men and women.
        Stroke. 2007; 38: 1744-1751
        • Liu J.
        • Grundy S.M.
        • Wang W.
        • et al.
        Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome.
        Am Heart J. 2007; 153: 552-558
        • Ninomiya T.
        • Kubo M.
        • Doi Y.
        • et al.
        Impact of metabolic syndrome on the development of cardiovascular disease in a general Japanese population: the Hisayama study.
        Stroke. 2007; 38: 2063-2069
        • Wang J.
        • Ruotsalainen S.
        • Moilanen L.
        • et al.
        The metabolic syndrome predicts incident stroke: a 14-year follow-up study in elderly people in Finland.
        Stroke. 2008; 39: 1078-1083
        • Qiao Q.
        • Laatikainen T.
        • Zethelius B.
        • et al.
        Comparison of definitions of metabolic syndrome in relation to the risk of developing stroke and coronary heart disease in Finnish and Swedish Cohorts.
        Stroke. 2009; 40: 337-343
        • Mi D.
        • Zhang L.
        • Wang C.
        • et al.
        Impact of metabolic syndrome on the prognosis of ischemic stroke secondary to symptomatic intracranial atherosclerosis in Chinese patients.
        PLoS ONE. 2012; 7: e51421
        • Hanchaiphiboolkul S.
        • Suwanwela N.C.
        • Poungvarin N.
        • et al.
        Risk of metabolic syndrome for stroke is not greater than the sum of its components: Thai Epidemiologic Stroke (TES) study.
        J Stroke Cerebrovasc Dis. 2013; 22: e264-e270
        • Mi D.
        • Jia Q.
        • Zheng H.
        • et al.
        Metabolic syndrome and stroke recurrence in Chinese ischemic stroke patients–the ACROSS-China study.
        PLoS ONE. 2012; 7: e51406
        • Balti E.V.
        • Kengne A.P.
        • Fokouo J.V.
        • et al.
        Metabolic syndrome and fatal outcomes in the post-stroke event: a 5-year cohort study in Cameroon.
        PLoS ONE. 2013; 8: e60117
        • Hanefeld M.
        • Koehler C.
        • Gallo S.
        • et al.
        Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study.
        Cardiovasc Diabetol. 2007; 6: 13
        • Ninomiya T.
        • Kubo M.
        • Doi Y.
        • et al.
        Impact of metabolic syndrome on the development of cardiovascular disease in a general Japanese population: the Hisayama study.
        Stroke. 2007; 38 (Epub 2007 May 24): 2063-2069
        • Arenillas J.F.
        • Moro M.A.
        • Dávalos A.
        The metabolic syndrome and stroke: potential treatment approaches.
        Stroke. 2007; 38: 2196-2203
        • Berg A.H.
        • Scherer P.E.
        Adipose tissue, inflammation, and cardiovascular disease.
        Circ Res. 2005; 96: 939-949